

Published in final edited form as:

*Anal Biochem.* 2008 December 1; 383(1): 116–121. doi:10.1016/j.ab.2008.07.037.

## Signal Amplification of Target Protein on Heparin Glycan Microarray

Tae-Joon Park<sup>a,†</sup>, Moo-Yeal Lee<sup>d,†</sup>, Jonathan S. Dordick<sup>a,\*</sup>, and Robert J. Linhardt<sup>a,b,c,\*</sup>

<sup>a</sup>Department of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110, 8<sup>th</sup> Street, Troy, NY 12180 (USA)

<sup>b</sup>Department of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110, 8<sup>th</sup> Street, Troy, NY 12180 (USA)

<sup>c</sup>Department of Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110, 8<sup>th</sup> Street, Troy, NY 12180 (USA)

<sup>d</sup>Solidus Biosciences, Inc., 1223 Peoples Ave., Troy, NY 12180 (USA)

### Abstract

A heparin glycan chip (HepGlyChip) with 4800-fold enhanced signal-to-noise ratio as compared to the control without heparin was developed for high-throughput analysis of heparin-protein interactions for new drug development and for the screening biological samples in diagnostic applications. As a proof of concept, a heparin glycan microarray was prepared on a poly (styrene-*co*-maleic anhydride) (PS-MA)-coated glass slide. Heparin was covalently immobilized on poly-L-lysine (PLL) layer with multiple binding sites by sulfo-ethylene glycol bis(succinimidylsuccinate) (sulfo-EGS), increasing the signal to noise ratio, minimizing non-specific binding of target proteins, and resulting in a 3-dimensional (3D) structure on the HepGlyChip. This on-chip signal amplification platform was successfully demonstrated by probing the heparin microarray with the highly specific heparin-binding protein, antithrombin III (AT III).

### Introduction

The application of combinatorial methods for synthesis in drug discovery enables efficient *in vitro* and *in vivo* testing of potential drugs. Advances in genomics, proteomics and glycomics have dramatically increased developments in high-throughput screening methods, resulting in a direct impact on the evaluation of toxicity tests and metabolic pathways of drug targets [1]. Despite these advances, carbohydrate microarrays still pose considerable challenges because carbohydrate-protein interactions are often relatively weak compared to DNA-DNA, DNA-

© 2008 Elsevier Inc. All rights reserved.

\*To whom correspondence should be addressed: Biotechnology 4005, Rensselaer Polytechnic Institute, Troy, NY 12180 (USA), Fax: (+ 1) 518-276-3405, E-mail: linhar@rpi.edu, Fax: (+ 1) 518-276-2207, E-mail: dordick@rpi.edu.

<sup>†</sup>TJ Park and MY Lee contributed equally to this work.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

<sup>1</sup>*Abbreviations used:* GAG, glycosaminoglycan; LMW, low molecular weight; SPR, surface plasmon resonance; ITC, isothermal titration calorimetry; PS-MA, poly (styrene-*co*-maleic anhydride); PLL, poly-L-lysine; FITC, fluorescein isothiocyanate; MES, 2-(4-morpholino)-ethane sulfonic acid; EDC, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide; NHS, N-hydroxysuccinimide; DMF, dimethyl formamide; EGS, ethylene glycol bis(succinimidylsuccinate); AT III, antithrombin III; HepGlyChip, heparin glycan chip; PBS, phosphate buffered saline; 2D, two-dimensional; 3D, three-dimensional.

RNA, and protein-protein interactions [2]. Hence, a new surface chemistry needs to be developed for carbohydrate microarrays that have a high signal to noise ratio and a high, localized concentration of carbohydrate to which proteins can bind [3].

Heparin, a linear, polydisperse, negatively charged, and highly sulfated glycosaminoglycan (GAG), and the structurally related low molecular weight (LMW) heparins, carry out a variety of important biological roles as anticoagulant drugs [4]. Heparan sulfate, a related GAG, also plays a critical role in developmental biology, controlling cell growth, cell differentiation, cellular adhesion and cell migration [5]. Even for biological activities closely associated with heparin or heparan sulfate, the progression to pharmaceutical and clinical application is slow because of the complex structures of these GAGs. X-ray crystallography, NMR spectroscopy, hemagglutination inhibition assay, enzyme-linked lectin assay, surface plasmon resonance (SPR) spectroscopy and isothermal titration calorimetry (ITC) have been used to monitor carbohydrate-protein interactions [3,5,6]. Since the first carbohydrate microarray appeared in the literature in 2002, such microarrays have been promising tools to probe carbohydrate-protein interactions, particularly in the developing field of glycomics [7–12]. Over a thousand spots on a microarray chip can be conveniently monitored using very small amounts of both ligand and analyte to elucidate the specific antibodies useful in the diagnosis of diseases, to identify inhibitors of carbohydrate-protein interactions, and to study events involving carbohydrate-cellular interactions [7–19]. Despite the importance of measuring binding events on carbohydrate microarrays, this technology has not been extensively applied to probe protein binding to GAGs because GAGs are heterogeneous molecules. GAG biosynthesis is poorly understood and difficult to control, and GAG-based signaling is still in very early stages of scientific study [8].

Two dimensional (2D) surface chemistries for site-specific and covalent immobilization generally result in low signal intensity and substantial non-specific binding of target proteins because of an insufficient number of binding sites and the presence of surface-protein interactions. Chip design using polymers such as hydrogels or dendrimers might provide a 3-dimensional (3D) structure with more binding sites required for signal amplification [20]. In this article, we demonstrate for the first time a poly-L-lysine (PLL)-based 3D system to immobilize a sufficient amount of heparins to provide the high signal intensity required for target protein on a heparin glycan chip (HepGlyChip).

## Materials and methods

### Preparation of FITC-labeled amino heparin

$\omega$ -Hydrazido-adipyl-azo heparin (amino heparin) was prepared from heparin (sodium salt, extracted from porcine intestinal mucosa, USP activity 169 U/mg, Celsus Laboratories, Cincinnati, Ohio) by reductive amination [21]. Thus, amino heparin contains a single amine group at the reducing end of the heparin chain, allowing the single point, oriented attachment of heparin chains. To prepare FITC-labeled amino heparin, 1 mL of 50 mg amino heparin in 0.05M 2-(4-morpholino)-ethane sulfonic acid (MES) buffer solution was activated with a mixture of 15 mg 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and 9 mg *N*-hydroxysuccinimide (NHS) for 15 min. A 0.1 mL of 0.1 M fluoresceinamine (Sigma) in dimethyl formamide (DMF) was added to the NHS-activated heparin. This 1.1 mL mixture was incubated overnight in the dark, and then dialyzed in the dark for 24 h. A column (2.5 × 80 cm) filled with a cation exchange resin (H<sup>+</sup> form, Sigma) was washed with 1.4 (equivalent to 2 packed bed volumes) of 1 M HCl. FITC-amino heparin reaction mixture was loaded in this column and FITC-amino heparin was eluted by washing with 700 mL of distilled water. The eluted FITC-amino heparin solution was neutralized with NaOH and then sodium chloride was added to obtain 16 % saline solution. Methanol (80 v/v %) was added to precipitate the

FITC-amino heparin and the recovered precipitate was dissolved in water and dialyzed for 48 h to obtain pure FITC-amino heparin.

### **Preparation of antithrombin III (AT III)-immobilized Sepharose beads to separate low and high affinity heparins**

AT III (2 mg, purified from human plasma, specific activity > 6 U/mg, Aniara Corp., Mason, Ohio) was dialyzed in 200  $\mu$ L coupling buffer (0.1M NaHCO<sub>3</sub>/0.5 M NaCl, pH 8.3) at 4°C overnight. CNBr-activated Sepharose beads (3 mg, Sigma) were washed and swollen in cold 1 mM HCl for 40 min, washed with distilled water and then washed with 0.1 M NaHCO<sub>3</sub>/0.5 M NaCl (pH 8.3) coupling buffer. A 100 mg of heparin was added to dialyzed AT III solution in the coupling buffer to protect the active site of AT III. The coupling reaction was performed by mixing the AT III solution with CNBr-activated beads for 2 h at room temperature and then for 24 h at 4°C with gentle shaking. The mixture was filtered using a 0.8  $\mu$ m polycarbonate filter to recover the beads and then residual AT III and heparin were immediately removed by washing the beads with the coupling buffer. Unreacted CNBr-activated groups were blocked with 0.2 M glycine (pH 8.0) for 2 h at room temperature. The glycine solution was removed by washing with a basic coupling buffer solution (0.1 M NaHCO<sub>3</sub>/0.5 M NaCl) at pH 8.5, then with an acetate buffer solution (0.1 M, pH 4) containing 0.5 M NaCl.

### **Separation of high and low affinity heparin**

A column packed with 10 mL of AT III-Sepharose beads was washed with the basic coupling buffer solution, and then with the acetate buffer solution. The AT III-Sepharose column was equilibrated in 50 mM Tris equilibrium buffer with HCl (pH 8.5) containing 0.3 M NaCl and 10  $\mu$ L of heparin (10 mg/mL) was then loaded. Low and high affinity heparins were obtained by eluting with 20 mL of the equilibrium buffer and then 20 mL of 50 mM Tris buffer with HCl (pH 8.5) containing 2.8 M NaCl, respectively.

### **Preparation of FITC-labeled AT III**

AT III (1 mL, 2 mg/mL) was exchanged into 50 mM sodium borate buffer (pH 8.5) by dialysis. A fluorescein labeling reagent, NHS-fluorescein (830 nmol, Pierce) in 100  $\mu$ L of DMF, was added to the AT III solution (24-fold molar excess). The reaction mixture was mixed well and incubated for 1 h at room temperature and then dialyzed against distilled water.

### **Purification of FITC-labeled AT III by heparin-agarose beads**

A column packed with 2 mL of heparin-agarose (Sigma) was equilibrated with 6 mL of 20 mM Tris buffer with HCl (pH 7.3) containing 0.15 M NaCl. FITC-labeled AT III in the equilibration buffer solution was applied to the column and then washed with 4 mL of the equilibration buffer to remove inactivated AT III. The active FITC-labeled AT III bound to the column was eluted with 6 mL of 20 mM Tris buffer with HCl (pH 7.3) containing 2 M NaCl and dialyzed against 10 mM phosphate-buffered saline (PBS) containing 15 mM NaCl (pH 7.1).

### **Modification of a microscopic glass slide**

Borosilicate microscope slides (25  $\times$  75 mm<sup>2</sup>, Fisher, Pittsburgh, PA) were pretreated with ethanol, followed by concentrated H<sub>2</sub>SO<sub>4</sub> overnight to remove dust and oil from the glass surface. The slides were then sonicated for 30 min, rinsed with distilled water five-times, and then immersed twice in acetone. The acid-cleaned slides were dried for 30 min in an oven at 120°C. Finally, the acid-cleaned slides were spin-coated (WS-400B-6NPP/Lite, Laurell Co., North Wales, PA) with 1.5 mL of 0.1 % (w/v) poly(styrene-*co*-maleic anhydride) (PS-MA, Sigma, St. Louis, MO) in toluene for 30 sec at 3000 rpm. The PS-MA coating provides a reactive functionality to covalently attach poly-L-lysine (PLL, Sigma) while enhancing hydrophobicity of the slide surface [22].

### Microarraying of amino heparin to prepare the HepGlyChip

To immobilize amino heparin on PLL (3D system), 30 nL of 0.01% PLL solution (mol wt 70,000 – 150,000, Sigma) was spotted onto the PS-MA-coated slides (40 × 14 spot array, 560 spot/slide) using a MicroSys™ 5100-4SQ microarrayer (DIGILAB Genomic Solutions, Ann Arbor, MI). Following spotting and drying of PLL spots, 30 nL of up to 10 mg/mL sulfo-ethylene glycol bis(succinimidylsuccinate) (EGS) (Pierce, Rockford, IL) was spotted atop each PLL spot. Amino heparin was covalently attached by spotting 30 nL of up to 10 mg/mL amino heparin on top of PLL-EGS spots (Scheme 1A). To quench unreacted amine groups on PLL and remaining reactive groups on sulfo-EGS, 30 nL of succinic anhydride (0.2 mg/mL) and 30 nL of Tris buffer (2 mg/mL) were spotted sequentially. The 3D HepGlyChip was rinsed 3 times in a washing buffer (10 mM PBS, pH 7.1) for 30 min, followed by incubation for 24 h at 4°C in a blocking solution (SuperBlock™, Pierce, Rockford, IL). Amino heparin was covalently attached by spotting 30 nL of up to 10 mg/mL amino heparin on PS-MA slides to directly immobilize it in the 2D system (Scheme 1B). Spots containing no amino heparin were used as control. The 2D HepGlyChip was rinsed in the washing buffer, followed by incubation in the blocking solution.

### Incubation of the HepGlyChip in FITC-labeled AT III solution to study heparin-protein interaction

The HepGlyChip washed with the blocking solution was rinsed 3 times in the washing buffer solution for 30 min before protein binding. The HepGlyChip was incubated in 1 mL of 10 µg/mL FITC-labeled AT III solution for 1 h at room temperature, followed by rinsing 3 times in the washing buffer for 30 min and then washing 3 times with distilled water for 5 min. To detect the location of each heparin spot where heparin-AT III interactions occurred, the entire HepGlyChip was scanned using blue laser (excitation: 488 nm) and standard blue filter (emission: 508 ~ 560 nm) for green FITC dye in GenePix® Professional 4200A scanner (Molecular Devices Co., Sunnyvale, CA). The green fluorescence intensity of the spots was quantified from the scanning image using GenePix Pro 6.0 (Molecular Devices Co.). The data points were plotted from an average of six spots (Fig. 1, Fig. 3 and Fig. 4) or eight spots (Fig. 2) and the standard errors are presented.

## Results and Discussion

The most critical issue in chip technologies designed to study heparin-protein interactions is a low signal-to-noise ratio resulting from the non-specific binding of target proteins to the surface [2,3,5,6,20]. A 3D microarray system, prepared using PLL with multiple amino groups, was used to address this problem. This 3D system provides higher heparin binding capacity for probing heparin-specific proteins, thus reducing non-specific interactions between the slide surface and the proteins. PLL microarrays on the PS-MA coating were prepared by a simple spotting and drying technique. A highly hydrophobic amino-reactive PS-MA coating was used to covalently immobilize PLL while simultaneously preventing the spreading of aqueous spots on the surface of the glass slide (Scheme 1A). PLL increases the number of binding sites for heparin, amplifying signal intensity. Immobilized PLL was next modified with a homo bi-functional cross-linker, sulfo-EGS, and then an amino heparin derivative, ω-hydrazido-adipyl-azo heparin, was covalently attached (Scheme 2).

FITC-labeled amino heparin, at concentrations ranging from 8.3 nM (100 ng/mL) to 830 µM (10 mg/mL), was printed on top of the spots containing EGS-coupled PLL on the PS-MA slides to demonstrate immobilization of heparin on PLL (Fig. 1). After immobilizing FITC-labeled amino heparin, the residual amino groups on PLL were quenched by succinylation with succinic anhydride to remove potential ionic interactions between PLL and FITC-labeled amino heparin. As shown in Figure 1, after extensive washing in the PBS solution, the green

fluorescence intensity of the spots was found to increase with increasing concentrations of FITC-labeled amino heparin. The fluorescence intensity of FITC-labeled amino heparin was over three orders of magnitude higher than the control without heparin. Having dramatically increased signal-to-noise ratio with PLL, the surface chemistry was next optimized by varying the sulfo-EGS and amino heparin concentrations (Fig. 2). In each spot, containing 0.78 mM amine groups on PLL, the concentrations of sulfo-EGS and amino heparin were varied from 1.5 mM (0.1 mg/mL) to 150 mM (10 mg/mL) and from 8.3 nM (100 ng/mL) to 830  $\mu$ M (10 mg/mL), respectively. The spots without sulfo-EGS and amino heparin were used as the controls. After incubation of the slide in FITC-labeled AT III solution for 1 h and extensive rinsing in the wash buffer, the fluorescence intensity of FITC-labeled AT III in the spots where heparin-AT III interactions took place was quantified using a microarray scanner. As a result, fluorescence intensity of FITC-labeled AT III was increased more than 4800-fold as compared to that of the control (i.e., background fluorescent intensity representing non-specific protein binding).

Fluorescence intensity of AT III in the microarray spots containing heparin covalently attached on PLL (3D system) were compared with those in the spots containing heparin directly immobilized on the PS-MA slide (2D system) to investigate our on-chip amplification system using 3D PLL-heparin structure. As shown in Fig. 3, the 3D amplification system provided 100-fold increased signal-to-noise ratio compared to the 2D system.

Heparins having different affinity toward AT III were immobilized to further validate the 3D amplification system. To this end, we prepared microarray spots containing covalently immobilized high affinity heparin (> 95% high affinity chains), un-fractionated heparin (containing ~ 30% high affinity chains and ~70% low affinity chains), and low affinity heparin (< 1% high affinity chains) on the PLL-sulfo-EGS sites (Fig. 4). Thus, high affinity heparin should theoretically exhibit a 3-fold higher fluorescence intensity than that of unfractionated heparin. As a result, fluorescent intensities of AT III in the spots increased as affinity of heparin and concentration of heparin increased. Specifically, the intensity of low affinity heparin was close to 0, unfractionated heparin was approximately 1500, and high affinity heparin was around 5000 in the spots where 830 nM of heparin spotted. This result indicates that the difference of fluorescence between unfractionated heparin and high affinity heparin is close to theoretical ratio. The relative proportion of high affinity heparin chains in the spots was consistent with fluorescent intensities of FITC-labeled AT III at all concentrations tested. Thus, the surface chemistry we developed could be used to access affinity of heparin to a variety of heparin-binding proteins.

## Conclusions

A heparin glycan chip (HepGlyChip) has been developed on the PS-MA-functionalized slides to detect interactions between heparin and target proteins in the high-throughput manner. As a proof of concept, we successfully demonstrated specific interactions between heparin and AT III on the HepGlyChip, and the PLL-based 3D structure in the microarray spots provided enhanced signal to noise ratio and minimized non-specific binding of AT III. We are currently performing on-chip chemo-enzymatic synthesis of heparin in the spots for high-throughput screening of heparin analogs. This approach may provide valuable information on various structure-function relationships of thousand different glycans in microarrays on a single microscopic slide. Thus, the HepGlyChip platform might facilitate the development of the next generation of heparin-based drugs for anticoagulant/antithrombotic applications and beyond. We envision that in the near future the HepGlyChip platform could be applied to glycomic studies for high-throughput screening of interactions with heparin-binding proteins. Printing drug candidates and various heparin-binding proteins together on a chip of heparin chains having different sequences might be useful in new drug development. Such microarray

technology might have utility in evaluating small molecule drugs that antagonize with heparin interaction with heparin-binding proteins. Finally, a HepGlyChip may facilitate rapid screening of biological samples for the diagnostic identification of heparin and heparin-binding proteins in biological fluids and tissues.


## Acknowledgments

The authors thank the National Institutes of Health for a grant (R41RR023764) supporting this research.

## Reference


1. Dobson CM. Chemical space and biology. *Nature* 2004;432:824–828. [PubMed: 15602547]
2. Shin I, Park S, Lee M-R. Carbohydrate microarrays: An advanced technology for functional studies of glycans. *Chem. Eur. J* 2005;11
3. Park S, Lee M-R, Shin I. Fabrication of carbohydrate chips and their use to probe protein-carbohydrate interactions. *Nat. Protoc* 2007;2:2747–2758. [PubMed: 18007610]
4. Linhardt RJ. Heparin: Structure and activity. *J. Med. Chem* 2003;46:2551–2554. [PubMed: 12801218]
5. Capila I, Linhardt RJ. Heparin - Protein interactions. *Angew. Chem. Int. Ed* 2002;41:391–412.
6. Park S, Lee M-R, Pyo S-J, Shin I. Carbohydrate chips for studying high-throughput carbohydrate-protein interactions. *J. Am. Chem. Soc* 2004;126:4812–4819. [PubMed: 15080685]
7. Noti C, de Paz JL, Polito L, Seeberger PH. Preparation and use of microarrays containing synthetic heparin oligosaccharides for the rapid analysis of heparin-protein interactions. *Chem. Eur. J* 2006;12:8664–8686.
8. Wang D. Carbohydrate microarrays. *Proteomics* 2003;3:2167–2175. [PubMed: 14595816]
9. Ban L, Mrksich M. On-chip synthesis and label-free assays of oligosaccharide arrays. *Angew. Chem. Int. Ed. Engl* 2008;47:3396–3399. [PubMed: 18383458]
10. Liang PH, Wu CY, Greenberg WA, Wong CH. Glycan arrays: biological and medical applications. *Curr. Opin. Chem. Biol* 2008;12:86–92. [PubMed: 18258211]
11. Stevens J, Blixt O, Paulson JC, Wilson IA. Glycan microarray technologies: tools to survey host specificity of influenza viruses. *Nat. Rev. Microbiol* 2006;4:857–864. [PubMed: 17013397]
12. Zhi ZL, Powell AK, Turnbull JE. Fabrication of carbohydrate microarrays on gold surfaces: direct attachment of nonderivatized oligosaccharides to hydrazide-modified self-assembled monolayers. *Anal. Chem* 2006;78:4786–4793. [PubMed: 16841896]
13. Flitsch SL, Ulijn RV. Sugars tied to the spot. *Nature* 2003;421:219–220. [PubMed: 12529622]
14. de Paz JL, Spillmann D, Seeberger PH. Microarrays of heparin oligosaccharides obtained by nitrous acid depolymerization of isolated heparin. *Chem. Commun* 2006;29:3116–3118.
15. Feizi T, Fazio F, Chai W, Wong C-H. Carbohydrate microarrays - a new set of technologies at the frontiers of glycomics. *Curr. Opin. Struct. Biol* 2003;13:637–645. [PubMed: 14568620]
16. de Paz JL, Seeberger PH. Recent advances in carbohydrate microarrays. *QSAR Comb. Sci* 2006;25:1027–1032.
17. de Paz JL, Noti C, Seeberger PH. Microarrays of synthetic heparin oligosaccharides. *J. Am. Chem. Soc* 2006;128:2766–2767. [PubMed: 16506732]
18. Noti C, de Paz JL, Polito L, Seeberger PH. Preparation and use of microarrays containing synthetic heparin oligosaccharides for the rapid analysis of heparin-protein interactions. *Chem. Eur. J* 2006;12:8664–8686.
19. de Paz JL, Moseman EA, Noti C, Polito L, von Andrian UH, Seeberger PH. Profiling heparin-chemokine interactions using synthetic tools. *ACS. Chem. Biol* 2007;2:735–744. [PubMed: 18030990]
20. Seurynck-Servoss SL, White AM, Baird CL, Rodland KD, Zangar RC. Evaluation of surface chemistries for antibody microarrays. *Anal. Biochem* 2007;371:105–115. [PubMed: 17718996]
21. Nadkarni VD, Pervin A, Linhardt RJ. Directional immobilization of heparin onto beaded supports. *Anal. Biochem* 1994;222:59–67. [PubMed: 7856872]

22. Lee M-Y, Kumar RA, Sukumaran SM, Hogg MG, Clark DS, Dordick JS. Three-dimensional cellular microarray for high-throughput toxicology assays. *Proc. Nat. Acad. Sci. USA* 2008;105:59–63. [PubMed: 18160535]




**Figure 1.**

Fluorescent intensity of immobilized FITC-labeled amino heparin as a function of spotted heparin concentration. The concentrations of printed FITC-labeled amino heparin in the spots varied at a range from 8.3 nM (100 ng/mL), 83 nM (1  $\mu\text{g/mL}$ ), 830 nM (10  $\mu\text{g/mL}$ ), 8.3  $\mu\text{M}$  (100  $\mu\text{g/mL}$ ), 83  $\mu\text{M}$  (1 mg/mL), and 830  $\mu\text{M}$  (10 mg/mL), respectively. Spots containing no FITC-labeled amino heparin were used as control.




**Figure 2.**

The optimization of fluorescence intensity of bound FITC-labeled antithrombin (AT) III as a function of sulfo-ethylene glycol bis(succinimidylsuccinate) (EGS) and amino heparin concentrations. (A) A scanning image of the slide (3D system) where the printed concentrations of sulfo-EGS and amino heparin varied from 1.5 mM (0.1 mg/mL) to 150 mM (10 mg/mL) and at 0 mM (control), and from 8.3 nM (100 ng/mL), 83 nM (1  $\mu$ g/mL), 830 nM (10  $\mu$ g/mL), 8.3  $\mu$ M (100  $\mu$ g/mL), 83  $\mu$ M (1 mg/mL), 830  $\mu$ M (10 mg/mL), respectively. Spots containing no amino heparin were used as control. (B) An average of fluorescent intensity of bound FITC-labeled AT III in the spots at different concentration of sulfo-EGS and amino heparin printed (3D system).




**Figure 3.**

Comparison of fluorescent intensity of bound FITC-labeled AT III on the 3D and 2D system. (A) A scanning image of the spots containing FITC-labeled AT III bound on PLL-heparin structure (3D system). (B) A scanning image of the spots containing FITC-labeled AT III bound on heparin directly attached on the glass surface (2D system). (C) Comparison of fluorescent intensity on 3D amplification system (●) and 2D system (■). The spots containing 0.78 mM PLL were activated with 150 mM sulfo-EGS, followed by printing amino heparin at a range varying from 0.83 nM (10 ng/mL), 8.3 nM (100 ng/mL), 83 nM (1 μg/mL), 830 nM (10 μg/mL), 8.3 μM (100 μg/mL), and 83 μM (1 mg/mL), respectively. Spots containing no FITC-labeled amino heparin were used as control. The slide was incubated in an aqueous solution containing 8 μM AT III for 1 h to probe heparin-specific protein interaction.




**Figure 4.**

Fluorescence intensity of bound FITC-labeled AT III in the spots containing immobilized heparin with different percentages of high affinity chains: high affinity heparin (■), unfractionated heparin (●), and low affinity heparin (▲). The spots containing 0.78 mM amine groups on PLL were activated with 150 mM sulfo-EGS, followed by covalent immobilization of heparin with different affinity at a range varying from 0.83 nM (10 ng/mL) to 0.83  $\mu$ M (10  $\mu$ g/mL). Spots containing no FITC-labeled amino heparin were used as control. The slide was incubated in an aqueous solution containing 8  $\mu$ M AT III for 1 h to probe heparin-specific protein interaction.



**Scheme 1.**

The schematic representation of the PS-MA coating. (A) Immobilization of poly-L-lysine (PLL) on the PS-MA coating for signal amplification system (3D system) and (B) direct immobilization of amino heparin on the PS-MA coating (2D system).

**Scheme 2.**

Preparation of 3D and 2D HepGlyChips for heparin-AT III interaction. (A) 3D HepGlyChip constructed on PS-MA coating-PLL-EGS-heparin and (B) 2D HepGlyChip prepared on PS-MA coating-heparin.